ICU · Haematology / coagulation
Anticoagulants & Antiplatelets — Heparin, DOACs, Warfarin & Reversal
Also known as Heparin · Unfractionated heparin · UFH · LMWH · Enoxaparin · Fondaparinux · DOAC · Dabigatran · Rivaroxaban · Apixaban · Edoxaban · Warfarin · Protamine · Idarucizumab · Andexanet alfa · PCC · Four-factor PCC · Antiplatelet · Aspirin · Clopidogrel · Ticagrelor · Prasugrel · Heparin-induced thrombocytopenia · HIT · 4Ts score · Argatroban · Bivalirudin · HAS-BLED · Vitamin K · Phytomenadione
The anticoagulants and the antiplatelets in the ICU: the heparins (the UFH — the antithrombin-mediated IIa or Xa, the APTT monitoring, the protamine reversal 1 mg per 100 U; the LMWH — the anti-Xa, the enoxaparin 1 mg per kg BD, the partial protamine reversal about 60 per cent, the avoid the CrCl under 30; the fondaparinux — the not reversible); the DOACs (the dabigatran — the direct IIa — the idarucizumab 5 g; the apixaban, the rivaroxaban, the edoxaban — the direct Xa — the andexanet alfa or the PCC); the warfarin (the vitamin-K antagonist, the INR — the reversal the vitamin K 10 mg IV plus the PCC 25 to 50 IU/kg, the FFP the slower); the antiplatelets (the aspirin — the COX-1, the irreversible 7 to 10 days — the platelet transfusion; the clopidogrel, the prasugrel, the ticagrelor — the P2Y12 — the platelet transfusion); the heparin-induced thrombocytopenia (the 4Ts the score, the argatroban or the bivalirudin); the bleeding risk (the HAS-BLED). The reversal in the major bleed or the emergency surgery — the stop the agent, the specific the reversal (the protamine, the idarucizumab, the andexanet, the PCC plus the vitamin K, the platelets), the supportive.
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Meet the patient
A 76-year-old woman on warfarin for atrial fibrillation is brought in with right-sided weakness and slurred speech, GCS 11. The CT shows a 35 mL left basal-ganglia intracerebral haemorrhage. Her INR is 7.2. On the next bed, a 68-year-old man on dabigatran 150 mg twice daily has a similar spontaneous bleed. The two patients need two different reversal strategies in the next ten minutes — 4F-PCC plus vitamin K for the warfarin, idarucizumab 5 g IV for the dabigatran.[1][5]
Two questions decide every anticoagulant-related major bleed: what is the agent? (warfarin, dabigatran, an Xa-inhibitor, or heparin — each has its own antidote) and is this life-threatening or critical-organ bleeding? (intracerebral, retroperitoneal, tamponade, compartment, shock) — because reversal agents carry a thrombotic cost and are reserved for bleeds that meet that bar.[1][11]
References23ShowHide
- [1]Steiner T, Poli S, Griebe M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial Lancet Neurol, 2016.PMID 27302126
- [2]Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med, 2009.PMID 19717844
- [3]Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med, 2011.PMID 21830957
- [4]Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med, 2011.PMID 21870978
- [5]Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis N Engl J Med, 2017.PMID 28693366
- [6]Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors N Engl J Med, 2019.PMID 30730782
- [7]Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia Arch Intern Med, 2003.PMID 12912723
- [8]Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings J Thromb Haemost, 2006.PMID 16634744
- [9]Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest, 2010.PMID 20299623
- [10]Kuramatsu JB, Sembill JA, Gerner ST, et al. Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves Eur Heart J, 2018.PMID 29529259
- [11]Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee J Am Coll Cardiol, 2020.PMID 32680646
- [12]Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study Circulation, 2013.PMID 23935011
- [13]Cascone AE, Daley MJ, Pan N, et al. Low-dose versus standard-dose four-factor prothrombin complex concentrate for factor-Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage Pharmacotherapy, 2021.PMID 33866591
- [14]Levy JH, Ghadimi K, Kizhakkedathu JN, et al. What's fishy about protamine? Clinical use, adverse reactions, and potential alternatives J Thromb Haemost, 2023.PMID 37062523
- [15]Dobesh PP, Bhatt SH, Trujillo TC, et al. Antidotes for reversal of direct oral anticoagulants Pharmacol Ther, 2019.PMID 31521696
- [16]Chang DN, Dager WE, Chin AI Removal of dabigatran by hemodialysis Am J Kidney Dis, 2013.PMID 23219111
- [17]Britt RB, Brown JN Characterizing the Severe Reactions of Parenteral Vitamin K1 Clin Appl Thromb Hemost, 2018.PMID 28301903
- [18]Hanslik T, Prinseau J The use of vitamin K in patients on anticoagulant therapy: a practical guide Am J Cardiovasc Drugs, 2004.PMID 14967065
- [19]Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial Lancet, 2016.PMID 27178479
- [20]Heo YA Andexanet Alfa: First Global Approval Drugs, 2018.PMID 29926311
- [21]Samama MM, Cohen M, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients N Engl J Med, 1999.PMID 10477777
- [22]Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers Circulation, 2002.PMID 12427650
- [23]Suelzu S, Cossu A, Pala G, et al. Impact of different dosage of protamine on heparin reversal during off-pump coronary artery bypass: a clinical study Heart Lung Vessel, 2015.PMID 26495270